	US 11,987,629 B2
	Compositions and uses thereof for treating disease or condition
Lieping Chen, Beijing (CN); and Liqun Luo, Beijing (CN)
Assigned to Tayu Huaxia Biotech Medical Group Co., Ltd., Beijing (CN)
Appl. No. 15/733,838
Filed by Tayu Huaxia Biotech Medical Group Co., LTD, Beijing (CN)
PCT Filed May 31, 2019, PCT No. PCT/CN2019/089606 § 371(c)(1), (2) Date Nov. 30, 2020, PCT Pub. No. WO2019/228514, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. PCT/CN2018/089672 (WO), filed on Jun. 1, 2018; and application No. PCT/CN2018/099556 (WO), filed on Aug. 9, 2018.
Prior Publication US 2021/0214444 A1, Jul. 15, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 9/19 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 9/19 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/76 (2013.01)]

20 Claims

1. A method of treating a cancer in an individual, comprising administering to the individual an effective amount of an anti-PD-L1 antibody agent, wherein the anti-PD-L1 antibody agent comprises an antibody moiety comprising a heavy chain variable region (V_H) and a light chain variable region (V_L), wherein:

a) the V_Hcomprises a heavy chain complementarity determining region (HC-CDR) 1 comprising the amino acid sequence of SEQ ID NO: 41, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 42, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43; and

b) the V_Lcomprises a light chain complementarity determining region (LC-CDR) 1 comprising the amino acid sequence of SEQ ID NO: 44, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 46.